HOME >> MEDICINE >> NEWS
Drug treatment before angioplasty or stent placement not beneficial for heart attack patients

A common practice for improving outcomes in patients with sudden heart attack actually offers no benefit and could cause harm, according to a review of randomised trials published online today (Tuesday February 14, 2006) by The Lancet.

Despite the lack of evidence for its safety and effectiveness, many doctors believe the practice of giving patients with sudden ST-elevation* heart attack drugs before undergoing emergency revascularisation procedures (angioplasty or stent placement**) improves outcome. However, preliminary studies have suggested this practice confers no benefit.

To investigate the effect of pre-intervention drug treatment, Ellen Keeley (University of Texas Southwestern Medical Center, Dallas, TX, USA) and colleagues reviewed data from 17 trials comparing the outcomes for ST-elevation heart attack patients assigned the drug based procedure before angioplasty/stent placement (2237) and those assigned angioplasty/stent placement alone (2267). The investigators found that more of the patients who received drugs prior to their intervention died than those who did not receive medication (106 versus 78). Pre-intervention drugs also increased the risk of non-fatal heart attack, bleeding, stroke, and the need for repeat revascularisation treatment. These increased rates were mainly seen when the pharmacological treatment was a drug that dissolved clots (thrombolytic therapy).

Dr Keeley states: "Drug facilitated angioplasty or stent placement offers no benefit over primary intervention in ST-elevation heart attack and should not be used outside the context of randomised controlled trials. Furthermore facilitated interventions with thrombolytic-based regimens should be avoided." (Quote by e-mail; not in paper)

In an accompanying Comment Drs. Gregg Stone (Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA) and Bernard Gersh (Mayo Clinic, Rochester, MN, USA) state: "The results of thi
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
13-Feb-2006


Page: 1 2

Related medicine news :

1. Spot on treatment for acne
2. New treatment boosts muscle function in myasthenia gravis
3. New treatment effective in counteracting cocaine-induced symptoms
4. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
5. Preventive treatments in elderly people needs rethinking
6. Osteoporosis screening and treatment may be cost-effective for selected older men
7. Quality of treatment guidelines
8. Green tea holds promise as new treatment for inflammatory skin diseases
9. Many heart attack patients still not getting emergency clot-busting treatment
10. Electric fields have potential as a cancer treatment
11. New algorithm matches any tumor cells to best possible anti-cancer treatments

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Steven Douglas ... Taste of South Florida Event, an upscale fundraiser held in South Florida. The Inaugural ... and guests alike. This year the event will be held in a new, more ...
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products announces ... mobility device, the StandUp Walker. Made entirely in the USA, the StandUp Walker ... years. , StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of a ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus ... the continuation of the ‘Pay It Forward’ program into 2016. BioPlus partners with ... our specialty pharmacy. , “Since our Pay It Forward program began, we ...
(Date:2/9/2016)... Milwaukee, WI (PRWEB) , ... February 09, 2016 ... ... Bon-Ton, Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it ... Medical College of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University ...
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... ... cold therapy products, announced today the introduction of the newly designed, innovative shoulder ... comfort and better cold therapy coverage for the injured arm and shoulder to ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
(Date:2/9/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... full year financial results on Tuesday, February 23, 2016, ... will host a live audio webcast immediately following the ... fourth quarter and full year 2015 financial results and ... 2016 financial results. www.jazzpharmaceuticals.com .  Please connect ...
(Date:2/9/2016)... Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical ... announced further details of three new clinical trials ... Lewy body dementia, a disease affecting approximately 1.4 ... the three studies were recently initiated and the ... In addition, the Company reported financial results for ...
Breaking Medicine Technology:
Cached News: